Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

Morten Mau Soerensen,Willeke Ros,Maria E. Rodriguez-Ruiz,Debbie Robbrecht,Kristoffer Staal Rohrberg,Juan Martin-Liberal,Ulrik Lassen,Ignacio Melero Bermejo,Martijn P. Lolkema,Josep Tabernero,Christophe Boetsch,Hanna Piper-Lepoutre,Inja Waldhauer,Jehad Charo,Stefan Evers,Volker Teichgräber,Jan H. M. Schellens

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

2018

Morten Mau Soerensen
Willeke Ros
Maria E. Rodriguez-Ruiz
Debbie Robbrecht
Kristoffer Staal Rohrberg
Juan Martin-Liberal
Ulrik Lassen
Ignacio Melero Bermejo
Martijn P. Lolkema
Josep Tabernero
Christophe Boetsch
Hanna Piper-Lepoutre
Inja Waldhauer
Jehad Charo
Stefan Evers
Volker Teichgräber
Jan H. M. Schellens

e15155Background: High-dose (HD) IL-2 is approved for patients with melanoma and renal cell carcinoma but is associated with significant toxicity, given only in an inpatient setting. RO6874281 is a...

Keywords:

PK/PD models
Tumor-Associated Fibroblasts
Pathology
Fibroblast activation protein, alpha
Interleukin 2
Cancer research
Medicine
Renal cell carcinoma
Melanoma
antitumor activity
Toxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations